| Revenue growth | 15.2% Y-o-Y for FY26. |
|---|---|
| Margins | EBITDA margin 11.9% for FY26; impacted by raw material inflation. |
| Demand visibility | Healthy double-digit growth in HPPC, TSC, and AHN segments. |
| Management confidence | High, citing strong R&D and balanced end-market exposure. |
Growth
FY26 revenue grew 15.2% to ₹2,396.4 cr; PAT grew 9.4% to ₹149.2 cr. Q4 revenue surged 18.2% Y-o-Y.
Outlook
Unitop commissioned 15,000 MTPA ethoxylation capacity. FY27-28 focus on rephased capex, R&D at Koparkhairane, and international expansion.
Risks
Raw material price volatility and lag in passing on cost inflation impacted quarterly margins (11.3% vs 12.0% Y-o-Y).
Earnings Call filed with NSE, NSE: ROSSARI. Summary written with AI assistance from the document.
Rossari Biotech Ltd: key numbers
- Share price
- ₹423.20
- Market cap
- ₹2,344 Cr
- Revenue (annual)
- ₹2,396 Cr
- Net profit (annual)
- ₹149.2 Cr
- P/E (TTM)
- 15.6×Sector 37.2×
- Promoter holding
- 68.14%-0.01% QoQ
- FII holding
- 2.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Rossari Biotech Ltd
All →Rossari Biotech Investor Presentation: Key Takeaways
Rossari Biotech achieved its highest-ever quarterly revenue of Rs. 697.2 crore and EBITDA of Rs. 80.6 crore in Q1 FY27, driven by 28% YoY top-line growth and international expansion.
- Call
- Guides 15% growth
Rossari Biotech Other Announcement
Rossari Biotech filed its quarterly shareholding pattern for the quarter ended June 30, 2026. The filing notes a change in residential status for a promoter group member.
Rossari Biotech Management Change
Rossari Biotech Limited announced the appointment of Mr. Udeypaul Singh Gill and the re-appointment of Ms. Esha Padmanabhan Achan as Non-Executive Independent Directors.
Rossari Biotech Annual General Meeting
Rossari Biotech Limited held its 17th Annual General Meeting on July 20, 2026. All resolutions proposed in the AGM notice were passed with the requisite majority.
Rossari Biotech Results Update
Rossari Biotech reported Q1 FY27 consolidated revenue of ₹697.2 crore, up 28% YoY. It also established a new 5,000 MTPA greenfield blending facility in Thailand.
Rossari Biotech Earnings Call: Key Takeaways
Rossari Biotech reported record Q1 FY27 revenue of Rs. 697.2 cr (up 28.2% YoY) and EBITDA of Rs. 80.6 cr (up 18.7% YoY), driven by strong demand across core HPPC and TSC segments.